Jin Longyu

Cardiothoracic Surgeon

EDUCATION

M.D.: in Clinical medicine, Xiangya medical school, Central south university, 2011-2014

M.M.: in Clinical medicine, Xiangya medical school, Central south university, 2001-2004

Bachelor: in Clinical medicine, Hunan medical school, 1989-1994

ACADEMIC EXPERIENCE

Professor: the third Xiangya hospital, Central south university, 2014-Now

Associate Professor: the third Xiangya hospital, 2005-2013

Teaching fellow: the third Xiangya hospital, Central south university, 2000-2004

Teaching assistant: the third Xiangya hospital, Xiangya medical school, 1994-1999

SOCIAL ACTIVITIES

Visiting scholar: medical research center, Hormel institute, University of Minnesota, United States of American, J an. 2012 – Nov. 2012

Visiting Professor: thoracic surgery department, Cedars-Sinai Medical Center, United States of American, 1 Dec. 2012 – 31 Dec. 2012

Committee member: Branch of general thoracic surgery, Chinese medical doctor assoc-iation, 2013-2017

Committee member: Professional committee of thoracic surgery, Hunan province medical academic committee, 2012-2015

Vice Chairman of the Committee: Professional committee of esophagus disease, anticancer association of Hunan province, 2013-2016

RESEARCH AREA

Minimally invasive surgical treatment in thoracic disease

Comprehensive therapy of lung cancer

Molecular mechanism of lung cancer occurrence and development

Education management

TEACHING COURSES

Surgery

cardiovascular thoracic surgery

operative surgery

CONTACT ME

EMAIL: jinlongyu1123@163.com

PHONE: +86-731-88618220

PUBLICATION

[1] Jin ZX, Jin LY. Resveratrol mediates cell cycle arrest and cell death in human esophageal squamous cell carcinoma via derectly targeting EGFR signaling pathway. Oncology Letter (under review).

[2] Fang L, Zhu JL, Ma YC, Hong C, Xiao S, Jin LY. Net-1 functions as a potential prognostic marker for patients with non-small cell lung caner. Mol Med Report ( proofs)

[3] Jiang ZB, Zhu JL, Ma YC, Hong C, Xiao S, Jin LY. Tyrosylprotein sulfotransferase 1 expression is negatively correlated with c-Met and lymph node metastasis in human lung cancer.. Mol Med Report 12:5217-5222, 2015

[4] Ma, YC, Li C, Gao F, Xu Y, Jiang ZB , Liu JX , Jin LY. Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway. Oncol Rep, 31(3): 1343-1349, 2014.

[5] Zhou ZS,  Li M, Gao F, Peng JY, Xiao HB, Dai LX, Lin SR, Zhang Rand Jin LY. Arecoline suppresses HaCaT cell proliferation through cell cycle regulatory molecules. Oncol Rep, 29(6): 2438-2444, 2013.

[6] Jin LY, Li C, Xu Y, Wang L, Liu JX, Wang DJ, Hong C, Jiang ZB, Ma YC, Chen Q and Yu FL. Epigallocatechin gallate promotes p53 accumulation and activity via the inhibition of MDM2-mediated p53 ubiquitination in human lung cancer cells. Oncol Rep, 29(5): 1983-1990, 2013.

[7] Xu Y, Cao LQ, Jin LY, Chen ZC, Zeng GQ, Tang CE, Li GQ, Duan CJ, Peng F, Xiao ZQ, and Li C. Quantitative Proteomic Study of Human Lung Squamous Carcinoma and Normal Bronchial Epithelial Acquired by Laser Capture Microdissection. J Biomed Biotechnol, http://www.medsci.cn/sci/ journal.asp?id=27c-

83504. Article ID 510418, doi:10.1155/2012/510418, Volume 2012.

[8] Li XH, Zhu JL, Hong C, Zeng L, Deng LM and Jin LY. Effects of systematic rehabilitation programs on quality of life in patients undergoing lung resection. Molecular and Clinical Oncology. 1: 200-208, 2013.

[9] Xie HQ, Zhou JL, Zhou JD, Chen Y and Jin LY. Detection, biological effectiveness, and characterization of nanosilver-epidermal growth factor sustained-release carrier. African Journal of Pharmacy and Pharmacology 2013, 7(7), pp. 397-404.

[10] Chen Q, Wang L, Ma YC, Wu XN, Jin LY, Yu FL. Increased hepcidin expression in non-small cell lung cancer tissue and serum is associated with clinical stage. Thorac Cancer., 5(1):14-24, 2014【IF：0.65】

[11] Zhibin Jiang, Ping Hu, Jianxin Liu, Dianjun Wang, Longyu Jin, Chao Hong. Screening Preoperative Peptide Biomarkers for Predicting Postoperative Myocardial Infarction after Coronary Artery Bypass Grafting. PLOS ONE，e100149，9（1）1-8，2014.